FUNDAMENTALS · Fundamentals · IE Healthcare

Medtronic (MDT) Fundamentals 2026 — P/E 21.8x, Revenue Analysis | SniperIQ

Medtronic (MDT) is a IE-listed Healthcare company in Medical - Devices with a market capitalization of

04.8B, trading at $81.85 on the NYSE. This SniperIQ fundamentals page covers Medtronic's valuation (P/E 21.8x, P/B 2.1x), profitability (net margin 13.2%), revenue (
6.4B in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
04.8B
P/E (TTM)21.8x
Net Margin13.2%
Revenue (FY26)
6.4B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Medtronic's market cap?

Medtronic (MDT) has a market capitalization of approximately

04.8B, trading at $81.85 on the NYSE. Market cap moves with the live share price.

What is Medtronic's P/E ratio?

Medtronic's trailing twelve-month P/E ratio is 21.8x, with a price-to-book (P/B) of 2.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Medtronic?

Medtronic runs a net profit margin of 13.2%, a gross margin of 65.0%, and an operating margin of 17.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Medtronic generate?

Medtronic reported revenue of

6.4B for fiscal year 2026, with net income of $4.8B and earnings per share (EPS) of 3.75. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Medtronic pay a dividend?

Medtronic offers a trailing dividend yield of about 3.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Medtronic financially healthy?

Medtronic carries a debt-to-equity ratio of 0.57x and a current ratio of 2.13x, with a market beta of 0.58. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Medtronic a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Medtronic (MDT) the key facts are: market cap

04.8B, P/E 21.8x, revenue
6.4B, 52-week range 73.31-106.33. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Medtronic's full fundamentals live

Get Medtronic's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Sanofi (SNY) fundamentals · Jeil Pharma Holdings (002620) fundamentals · Sanofi Consumer Healthcare India (SANOFICONR) fundamentals · Jupiter Life Line Hospitals (JLHL) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons